Medicare Enrolled
Dr. Larry Frase, M.D.
Medical Oncology · Longview, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Frase from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Frase? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Frase
Dr. Larry Frase is a medical oncology in Longview, TX, with 19 years in practice. Based on federal Medicare data, Dr. Frase performed 65,445 Medicare services across 3,912 unique beneficiaries.
Between the years covered by Open Payments, Dr. Frase received a total of $3,633 from 38 pharmaceutical and/or device companies across 113 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Frase is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 15% volume in TX$ $3,633 industry payments
Medicare Practice Summary
Medicare Utilization ↗65,445
Medicare services
Top 15% in TX for medical oncology
3,912
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,444 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 16,400 | $43 | $137 |
| Iron sucrose injection (Venofer) | 13,600 | $0 | $2 |
| Iron infusion (Feraheme) | 11,730 | $0 | $5 |
| Contrast dye for imaging (iodine-based) | 10,868 | $0 | $3 |
| Blood draw (venipuncture) | 1,869 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,635 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,502 | $10 | $64 |
| Office visit, established patient (20-29 min) | 1,367 | $62 | $250 |
| Dexamethasone injection (steroid) | 828 | $0 | $1 |
| Lactate dehydrogenase (enzyme) level | 780 | $6 | $31 |
| Immunoglobulin level test | 465 | $9 | $56 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 355 | $20 | $128 |
| Anti-nausea injection (Aloxi/palonosetron) | 280 | $1 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 221 | $97 | $707 |
| Office visit, established patient (30-39 min) | 182 | $95 | $368 |
| Microscopic examination for white blood cells with manual cell count | 162 | $4 | $22 |
| Complete blood count (CBC), automated | 162 | $6 | $34 |
| Ferritin level test (iron stores) | 159 | $13 | $60 |
| Beta-2 microglobulin (protein) level | 147 | $16 | $96 |
| Injection of additional new drug or substance into vein | 140 | $12 | $108 |
| Prothrombin time test (blood clotting) | 139 | $4 | $30 |
| Drug injection, under skin or into muscle | 128 | $11 | $96 |
| Injection, zoledronic acid, 1 mg | 126 | $7 | $431 |
| Injection, carboplatin, 50 mg | 120 | $2 | $300 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 103 | $22 | $157 |
| Thyroid stimulating hormone (TSH) test | 102 | $16 | $80 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 96 | $46 | $313 |
| Reticulated (young) platelet measurement | 95 | $35 | $143 |
| Carcinoembryonic antigen (cea) protein level | 93 | $19 | $99 |
| Thyroxine (thyroid chemical), total | 88 | $7 | $32 |
| Ct scan of chest with contrast | 85 | $51 | $821 |
| Iron level test | 85 | $6 | $27 |
| Iron binding capacity test | 85 | $9 | $35 |
| CT scan of abdomen and pelvis with contrast | 73 | $164 | $1,067 |
| Vitamin B-12 level test | 71 | $15 | $76 |
| Thyroid hormone evaluation | 64 | $6 | $30 |
| Injection of drug or substance into vein | 64 | $25 | $247 |
| Administration of chemotherapy into vein, each additional hour | 61 | $21 | $161 |
| Urinalysis with microscopic exam | 60 | $3 | $28 |
| Folic acid level test | 56 | $14 | $73 |
| Hospital follow-up visit, moderate complexity | 56 | $59 | $247 |
| Administration of additional new drug or substance into vein, 1 hour or less | 54 | $48 | $344 |
| CT scan of chest, without contrast | 52 | $48 | $686 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 51 | $91 | $657 |
| Injection, diphenhydramine hcl, up to 50 mg | 51 | $1 | $7 |
| Magnesium level test | 44 | $7 | $29 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 41 | $1,109 | $4,802 |
| Basic metabolic blood panel | 41 | $8 | $49 |
| Administration of additional new drug or substance into vein using push technique | 41 | $42 | $289 |
| Drawing of blood for a medical problem | 36 | $67 | $264 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 34 | $15 | $100 |
| Infusion, normal saline solution , 1000 cc | 34 | $2 | $19 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 32 | $362 | $1,722 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $23 | $145 |
| Ct scan of abdomen and pelvis without contrast | 27 | $73 | $560 |
| Red blood count, automated test | 27 | $4 | $23 |
| Unclassified drugs | 25 | $1 | $8 |
| Uric acid level test | 21 | $4 | $25 |
| Irrigation of implanted venous access drug delivery device | 19 | $18 | $114 |
| Initial hospital admission, high complexity | 17 | $133 | $694 |
| Chest X-ray, 2 views | 16 | $15 | $61 |
| Initial hospital admission, moderate complexity | 16 | $87 | $470 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $133 | $523 |
| New patient office visit (45-59 min) | 12 | $105 | $565 |
| Liver function blood test panel | 11 | $8 | $48 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
18.3% high complexity
66.1% medium
15.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,633
Total received (2018-2024)
Avg $727/year across 5 years
Bottom 49% in TX for medical oncology
38
Companies
113
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,940 (53.4%)
Other
Charitable contributions, space rental, and other categories
$1,529 (42.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$164 (4.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,067
2023$991
2022$522
2021$25
2018$28
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,298
NOVARTIS PHARMACEUTICALS CORPORATION
$299
ABBVIE INC.
$266
AstraZeneca Pharmaceuticals LP
$257
Pharmacyclics LLC, An AbbVie Company
$140
Janssen Biotech, Inc.
$106
GlaxoSmithKline, LLC.
$97
E.R. Squibb & Sons, L.L.C.
$97
Myriad Genetic Laboratories, Inc.
$93
Daiichi Sankyo Inc.
$91
Merck Sharp & Dohme LLC
$85
Bayer Healthcare Pharmaceuticals Inc.
$79
Tempus AI, Inc
$72
SOBI, INC
$65
Regeneron Healthcare Solutions, Inc.
$54
Aveo Pharmaceuticals, Inc.
$53
Blueprint Medicines Corporation
$49
Mirati Therapeutics, Inc.
$44
Gilead Sciences, Inc.
$28
PFIZER INC.
$28
Eisai Inc.
$26
Geron Corporation
$26
Incyte Corporation
$25
GENZYME CORPORATION
$25
JAZZ PHARMACEUTICALS INC.
$22
Jazz Pharmaceuticals Inc.
$20
Sun Pharmaceutical Industries Inc.
$19
MorphoSys, US Inc.
$18
Astellas Pharma US Inc
$17
CTI BioPharma Corp.
$17
Lilly USA, LLC
$17
Alnylam Pharmaceuticals Inc.
$17
Stemline Therapeutics Inc.
$17
EMD Serono, Inc.
$14
Seagen Inc.
$13
Alexion Pharmaceuticals, Inc.
$13
Global Blood Therapeutics, Inc.
$13
Seattle Genetics, Inc.
$12
Top 3 companies account for 51.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · CALQUENCE · DARZALEX · DOPTELET · Doptelet · ENHERTU · EPKINLY · Enhertu · FOTIVDA · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · JEMPERLI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LUTATHERA · Lenvima · MONJUVI · Nubeqa · OJJAARA · OPDIVO · OXBRYTA · OXLUMO · Odomzo · Orserdu · PADCEV · PLUVICTO · PROMACTA · PreciseTumor · RYTELO · SARCLISA · SCEMBLIX · SHINGRIX · Stivarga · TECVAYLI · ULTOMIRIS · VERZENIO · Vonjo · XALKORI · XT CDX · Xospata · ZEJULA · ZEPZELCA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (53%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $6 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
3.2
County median income
$64,809
Nearest hospital
CHRISTUS GOOD SHEPHERD MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Frase is a mixed practice specialist, with above-average Medicare volume (top 15% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Frase experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Frase performed 16,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Frase receive payments from pharmaceutical companies?
Yes. Dr. Frase received a total of $3,633 from 38 companies across 113 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Frase's costs compare to other medical oncologys in Longview?
Dr. Frase's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Frase) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Longview
Browse medical oncologys in Longview ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
NOVARTIS PHARMACEUTICALS CORPORATION Payments to Doctors
See all physicians who received payments from NOVARTIS PHARMACEUTICALS CORPORATION.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology